KC
AIMT

Kellner Capital’s Aimmune Therapeutics AIMT Stock Holding History

Kellner Capital’s Portfolio AIMT Stock Details AIMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-76,600
Closed -$2.64M – 40
2020
Q3 		$2.64M Buy
+76,600
New +$1.63M 1.43% 18

Kellner Capital's AIMT Position: Q4 2020 in Review

Kellner Capital sold out of Aimmune Therapeutics (AIMT) in Q4 2020, closing a stake of 76,600 shares — an estimated $2.64M sold.

Kellner Capital first reported a position in AIMT in Q3 2020 and held it in 1 quarter. The position peaked at $2.64M in Q3 2020. 0 funds tracked by Wall St. Rank hold AIMT as of Q4 2020.

  • Kellner Capital reported no remaining Aimmune Therapeutics position as of Q4 2020 after selling out during the quarter.
  • Kellner Capital sold 76,600 Aimmune Therapeutics shares in Q4 2020, an estimated $2.64M.
  • Kellner Capital first reported a position in Aimmune Therapeutics in Q3 2020 and held it in 1 quarter.
  • Kellner Capital's Aimmune Therapeutics position peaked at $2.64M in Q3 2020.
  • 0 funds tracked by Wall St. Rank held Aimmune Therapeutics as of Q4 2020.

Based on Kellner Capital's 13F filing for Q4 2020, filed 10 Feb 2021.